Microdosing psychedelics: A new frontier in mental health or just a placebo effect?

microdosing LSD

Exploring the potential of psychedelic drugs as a treatment for mental health conditions such as treatment-resistant depression, doctors and patients alike are increasingly turning to microdosing.

Despite growing anecdotal evidence suggesting enhanced mood, creativity, and productivity, the lack of regulatory standards and inconsistent research methods raises questions over safety, legality, and the possibility of an “expectancy effect.”

As these substances inch closer to decriminalization for medical use, the debate intensifies:

Are microdoses of psychedelics a breakthrough in mental health or merely a placebo?

Reported benefits of microdosing

Microdosing, a practice that involves consuming a fraction of a regular dose of psychedelic substances like LSD or psilocybin, has been associated with a wide range of anecdotal benefits.

Users claim that it enhances mood, creativity, concentration, productivity, and the ability to empathize.

However, these benefits could potentially be an “expectancy effect,” where a person feels happier and more productive simply because they expect the drug to have that effect.

What does microdosing refer to at all?

The exact definition of what constitutes a microdose is not universally agreed upon, complicating attempts to perform consistent research.

For substances like psilocybin, derived from mushrooms, it is usually considered to be around 0.3 grams compared to a medium-strength dose of 2 to 3 grams.

However, the potency of mushrooms can vary greatly due to lack of regulation.

LSD presents similar challenges.

It’s an invisible, tasteless, odorless substance that often comes in liquid form or embedded in paper. Without regulation, it’s nearly impossible to know the exact dosage one is taking.

Safety concerns also arise due to psychedelics’ potential for physiological tolerance. This suggests that even if microdosing has benefits, it might diminish over time if one stays at the same dosage.

What research says about microdosing

Research into psychedelics has been renewed recently after being curtailed by the War on Drugs in the late 1960s.

Psilocybin is generally thought safe at low dosages and has been used for centuries by indigenous peoples. The risk lies in potential poisoning from mistaking poisonous mushrooms for psilocybin ones.

Decriminalization could potentially increase the safety of psychedelics by allowing for regulation of cultivation and production.

Anticipation is growing that psychedelics like psilocybin and MDMA may become fully legalized for medical use under supervision.

Some, however, are concerned that unrestricted access might impact individuals with mental illnesses or even trigger conditions like psychosis in vulnerable people.

Therefore, the evidence for the benefits of microdosing is mixed.

While some studies indicate significant benefits, others suggest the effects at low doses are mostly expectancy effects and higher doses are needed for a therapeutic benefit.

For example, a study involving 34 patients found no objective evidence of improvements in creativity, well-being, and cognitive function with low-dose psilocybin.

That’s why you should make decisions to microdose in consultation with healthcare professionals.

It’s crucial to consider the legality and quality of the product, as well as the fact that definitive proof of the long-term safety and efficacy of microdosing is yet to be established.

Dosing and potency challenges

The use of psychedelics should be undertaken with caution. This particularly applies to patients with major mental illnesses like schizophrenia or bipolar disorder.

As a result, these patients are typically excluded from studies involving psychedelic drugs due to safety concerns.

Despite the potential benefits and growing popularity of microdosing, it is essential to remember that these substances remain largely illegal and unregulated.

This presents a significant risk both in terms of legal consequences and potential health risks due to variability in the potency and quality of the drugs.

The resurgence of research into psychedelics is promising, but the scientific community has yet to reach a consensus on the efficacy and safety of microdosing.

Future directions in psychedelic research

As research progresses, we hope that more concrete evidence will emerge, providing clearer guidelines for those considering this unconventional form of treatment.

While several cities and even a state have decriminalized psychedelics, it’s crucial to remember that decriminalization does not equate to safety or endorsement of use.

It merely reduces the legal penalties associated with their use.

Ultimately, it’s a personal choice whether to explore microdosing as a potential mental health treatment.

However, this decision should always be made in consultation with a healthcare professional and with full awareness of the potential risks involved.

Either way, one thing is for sure:

The story of microdosing is far from over.

As we edge closer to possible legalization and regulation, society must grapple with the implications of incorporating these powerful substances into mainstream medicine.

The hope is that responsible use, guided by robust scientific research, will ultimately prevail.

Thomas Reed

Thomas Reed

Dr. Thomas Reed, a seasoned medical expert from Boulder, Colorado, brings over two decades of experience in integrative medicine to Fine Healing Goods. He specializes in integrative medicine. His work combines conventional medical practices with holistic approaches to promote optimal health. Through his articles, Dr. Reed offers practical advice for achieving a balanced and healthy lifestyle.

Related articles

Most read articles

Get our articles

The latest Move news, articles, and resources, sent straight to your inbox every month.